India, Sept. 30 -- Shares of Molbio Diagnostics Ltd. jumped nearly 9% after Jefferies maintained coverage with a Rs1,600 target, putting the spotlight back on its post-IPO growth story. This article examines whether TrueNat's expansion, rising capacity utilization, operating leverage, and newer platforms such as OptraScan and Prorad can sustain the earnings growth projected by the brokerage.

Molbio Diagnostics was recently trading around Rs1,316 per share, with a market capitalization of roughly Rs15,147 crore and a P/E of around 70x. The stock's 52-week range was approximately Rs926-Rs1,687.

Also read: Can Steel Stocks Extend Their Rally? Tata Steel, JSW Steel and Jindal Steel in Focus as China and HRC Prices Hold the Key

TrueNat rem...